Jennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.

Similar documents
PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced

Slide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015

#O-16: Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV Coinfected Patients with Hepatic Cirrhosis

ICVH 2016 Oral Presentation: 28

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

2.0 Synopsis. Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, RBV M Clinical Study Report R&D/16/1328. (For National Authority Use Only)

HIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland

Amit Khatri, Sandeep Thomas Marbury, Richard A Preston, Lino Rodrigues, Haoyu Wang, Walid Awni, Rajeev Menon

Eliminating Hepatitis C from New Zealand

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Report on the Deliberation Results

Median (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)

Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals

Potential Issues in Treating HIV/HCV co-infection with new HCV antivirals

Comparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page:

Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters

Saeed Hamid, MD Alex Thompson, MD, PhD

HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)

1.0 Abstract. Title. Keywords

NEXT GENERATION DIRECT-ACTING ANTIVIRALS

Can we afford to Cure all HIV-HCV Co-infected Patients of HCV?

Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085

17 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 10, 2016 Washington, DC

Global Prevalence of HBV, HCV, HIV

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

What are the most promising opportunities for dose optimisation?

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Considerations for the management of Hepatitis C in patients with HIV co-infection

27-28 September 2017, Ljubljana, Slovenia. 3rd CEE Meeting on Viral Hepatitis and Co-infection with HIV

Learning Objective. After completing this educational activity, participants should be able to:

My HCV patient is co-infected with HIV: how to manage?

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster

Update in the Management of Hepatitis C: What Does the Future Hold

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Clinical Study Report AI Final 28 Feb Volume: Page:

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

Expert Perspectives: Best of HCV from EASL 2015

General Statement for Drugs for the Treatment of Hepatitis C

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons

Seyed Moayed Alavian Professor of Gastroenterology and Hepatology Editor in-chief of Hepatitis Monthly E mail:

Referring to Part of Dossier: Volume: Page:

HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON

Future strategies with new DAAs

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August

Description of Commitment

Summary of the risk management plan (RMP) for Viekirax (ombitasvir / paritaprevir / ritonavir)

Common Drug Review Clinical Review Report

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

HCV Treatment of Genotype 1: Now and in the Future

Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women

HIV/HCV Co-Infection

Patients with compensated cirrhosis: how to treat and follow-up

Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects

Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

Selecting HCV Treatment

Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Management of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY

Ledipasvir-Sofosbuvir (Harvoni)

Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University

Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men

Important new concerns or changes to the current ones will be included in updates of Symtuza's RMP.

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR

Treatment of chronic hepatitis C in HIV co-infected patients

Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects

Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens

Poster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD

Identifying Subgroups in Product Labeling: 2 Recent Case Studies. Martin King AbbVie

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS

T Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz

Second and third line paediatric ART strategies

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD

Darunavir STADA 400, 600 and 800 mg film-coated tablets , Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)

SYNOPSIS Final Clinical Study Report for Study AI444031

Summary of treatment benefits

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

SOLAR-1 (Cohorts A and B)

Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited

Approved regimens for cirrhotic patients

Hepatitis C Resistance Associated Variants (RAVs)

Treating Hepatitis C in Patients with Advanced Renal Disease

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation

Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin

Woman with Cervicitis

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

Transcription:

Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) Jennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc. 17 th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy Washington D.C., June 8-10, 2016

Disclaimers All the authors are AbbVie employees and may hold AbbVie stocks/options. The design, study conduct, analyses and financial support for the clinical trial were provided by AbbVie. 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 2

Background AbbVie s three direct acting antiviral (3D) regimen of ombitasvir (OBV), paritaprevir (PTV) co-dosed with ritonavir (r), and dasabuvir (DSV) with and without ribavirin (RBV) is approved for the treatment of chronic HCV genotype (GT) 1 infection in the US and EU among other countries/regions. The 2D regimen of OBV and PTV/r is approved for HCV GT1 in Japan and for the treatment of HCV GT4 among many countries/regions The 2D and 3D regimens are also approved for HCV/HIV-1 co-infected patients Co-administration of 3D with darunavir (DRV) In healthy volunteers, decreased DRV C 24 48% with QD and DRV C 12 43% with BID; DRV AUC and C max were comparable ( 24% difference) Not recommended in USPI 800 mg once daily administered at the same time as OBV/PTV/r + DSV can be used in the absence of extensive PI resistance in EU SmPC 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 3

TURQUOISE I (Study M14-004) Phase 2/3, randomized, open-label multicenter study to assess the safety and efficacy of 3D for 12 or 24 weeks in adults with HCV/HIV co-infection Part 1 evaluated a smaller group of subjects on various antiretroviral regimens to determine safety, efficacy and pharmacokinetics prior to dosing a larger group of subjects in Part 2 of the study Part 1a evaluated atazanavir or raltegravir in combination with 3D Part 1b evaluated darunavir 800 mg QD or 600 mg BID with 3D Intensive PK (0, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post dose) collected at: BL (Day-1) and Week 4 Sparse PK Sampling collected at Day 1 and Weeks 1, 2, 6, 8, 10 and 12 Plasma HIV RNA obtained at Day 1 and Weeks 1, 2, 4, 6, 8, 10 and 12 Ombitasvir/paritaprevir/r 25/150/100 mg QD + dasabuvir 250 mg BID + weight based RBV BID 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 4

Patient Demographics Arm C: DRV QD (n=10) Arm D: DRV BID (n=12) Age (years), median (range) 56 (44-65) 53 (34-68) Weight (kg), median (range) 77 (61-103) 81 (59-111) Sex, n (%) 8 Males (80%) 2 Females (20%) Race, n (%) 7 White (70%) 3 Black (30%) HCV GT 1 Subtype, n (%) 9 Subtype 1a (90%) 1 Subtype 1b (10%) 9 Males (75%) 3 Females (25%) 5 White (42%) 6 Black (50%) 1 Asian (8%) 6 Subtype 1a (50%) 6 Subtype 1b (50%) Cirrhosis, n (%) 0 (0%) 3 (25%) 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 5

Darunavir 800 mg QD Pharmacokinetic Parameters Darunavir Geometric mean (CV%) C max 0.92 (0.72, 1.18) Regimen (n=10) C max ng/ml AUC 24 ng h/ml C 24 ng/ml Day -1 DRV/r 800/100 mg QD 7376 (24) 86793 (25) 1625 (45) AUC 24 0.83 (0.71, 0.98) Week 4 DRV QD + 3D regimen 6816 (30) 72269 (27) 1045 (63) C 24 0.64 (0.44, 0.93) 0.25 0.50 0.75 1.00 1.25 1.50 Central Value Ratio and 90% CI 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 6

Darunavir 600 mg BID Pharmacokinetic Parameters Regimen (n=12) Darunavir Geometric mean (CV%) C max ng/ml AUC 12 ng h/ml C 12 ng/ml C max 0.92 (0.76, 1.12) Day -1 DRV/r 600/100 mg BID 8116 (35) 66097 (47) 3549 (62) AUC 12 0.88 (0.73, 1.05) Week 4 DRV BID + 3D regimen 7471 (41) 57914 (49) 2590 (67) C 12 0.73 (0.58, 0.92) 0.25 0.50 0.75 1.00 1.25 1.50 Central Value Ratio and 90% CI 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 7

Steady-State DRV Concentration-Time Curves Darunavir Concentration (ng/ml) 8000 7000 6000 5000 4000 3000 2000 1000 Arm C, Darunavir, Day -1 Arm C, Darunavir, Week 4 Darunavir Concentration (ng/ml) 10000 Arm C, Darunavir, Day -1 Arm C, Darunavir, Week 4 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (h) 9000 Arm D, Darunavir, Day -1 Arm D, Darunavir, Week 4 8000 1000 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (h) 10000 Arm D, Darunavir, Day -1 Arm D, Darunavir, Week 4 Darunavir Concentration (ng/ml) 7000 6000 5000 4000 3000 2000 1000 Darunavir Concentration (ng/ml) 0 0 2 4 6 8 10 12 Time (h) 1000 0 2 4 6 8 10 12 Time (h) 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 8

DRV 800 mg QD with the 3D Regimen in HCV/HIV Co-Infected versus DRV/r 800/100 mg QD in HIV-1 Mono-Infected Adults Darunavir 800 mg QD (Mean ± Standard Deviation) Patient Population HCV/HIV co-infected M14-004 Part 1b HIV mono-infected 1 (4 weeks of therapy) HIV mono-infected 1 (24 weeks of therapy) HIV mono-infected 1 (48 weeks of therapy) N C max (ng/ml) AUC 24 (ngxh/ml) C 24 (ng/ml) 10 7211 ± 2155 74916 ± 20029 1244 ± 782 9 5471 ± 1320 64230 ± 18210 1440 ± 514 13 5804 ± 1558 66950 ± 18610 1644 ± 727 10 6756 ± 1683 75620 ± 26440 1447 ± 706 1 Kakuda et al. J Antimicrob Chemother 2014 DRV C max, AUC 24 and C 24 when administered with 3D in HCV/HIV co-infected patients were comparable (<25% difference) to parameters when DRV/r was administer to HIV mono-infected adults. 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 9

DRV 600 mg BID with the 3D Regimen in HCV/HIV Co-Infected versus DRV/r 600/100 mg BID in HIV-1 Mono-Infected Adults Patient Population HCV/HIV co-infected M14-004 Part 1b N Darunavir 600 mg BID (Mean ± Standard Deviation) C max (ng/ml) AUC 12 (ngxh/ml) C 12 (ng/ml) 12 8037 ± 3291 65493 ± 32255 3470 ± 2339 HIV mono-infected 2 32 NA 62360 ± 25020 3559 ± 2385 a a. n = 26 2 Kakuda et al. AIDS Research and Treatment 2011 DRV AUC 12 and C 12 when administered with 3D in HCV/HIV co-infected patients were comparable ( 5% difference) to parameters when DRV/r was administer to HIV mono-infected adults 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 10

Maintenance of Plasma HIV-RNA Suppression At least one plasma HIV-1 RNA value 40 copies/ml and < 200 copies/ml occurred during the treatment period in: 2 of 10 (20%) of subjects receiving DRV QD 3 of 12 (25%) of subjects receiving DRV BID The highest HIV-1 RNA during the treatment period was 79 copies/ml in a subject enrolled into DRV QD All but one patient (in the DRV BID arm) had HIV-1 RNA suppression at the end of treatment; however, this patient maintained HIV-1 RNA <40 copies/ml at all other visits. No subjects in either treatment arm required a switch of their HIV-1 antiretroviral regimen due to loss of plasma HIV-1 RNA suppression. 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 11

DRV QD: DRV Trough Concentrations (C trough ) Relative to Plasma HIV RNA 60 DRV C troughs were available from 10 subjects over the treatment period 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 12

DRV BID: DRV C trough Relative to Plasma HIV RNA 63 DRV C troughs were available from 12 subjects over the treatment period 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 13

Geometric Mean (CV%) PK Parameters of DAAs, Ritonavir and Ribavirin DRV 800 mg QD (n=10) DRV 600 mg BID (n=12) Phase 1 Studies (n=113) Ombitasvir C max (ng/ml) 92.6 (35) 71.7 (38) 83-130 AUC 24 (ng h/ml) 1118 (36) 944 (40) 1050-1560 Paritaprevir C max (ng/ml) 1440 (106) 1244 (109) 771-3360 AUC 24 (ng h/ml) 7653 (139) 6714 (124) 3819-18600 Ritonavir C max (ng/ml) 881 (46) 941 (59) 1289-2240 AUC 24 (ng h/ml) 6909 (32) 15034 a 7571-14400 Dasabuvir C max (ng/ml) 725 (45) 572 (39) 826-1460 AUC 12 (ng h/ml) 4403 (48) 3509 (40) 5624-9790 Ribavirin C max (ng/ml) 2208 (25) 2813 (31) NA AUC 12 (ng h/ml) 21506 (27) 27373 (36) NA a Value is 2*AUC 12 to get estimated AUC 24 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 14

Geometric Mean (CV%) PK Parameters of DAAs, Ritonavir and Ribavirin Ombitasvir DRV 800 mg QD (n=10) DRV 600 mg BID (n=12) Phase 3 Studies (n=1277) 1 C trough (ng/ml) 20 (70) 21 (45) 24-33 Paritaprevir C trough (ng/ml) 19 (218) 44 (133) 16-36 Ritonavir C trough (ng/ml) 48 (76) NA 40-50 Dasabuvir C trough (ng/ml) 198 (33) 118 (46) 175-270 a Ribavirin C trough (ng/ml) 1606 (34) 1969 (44) 2060-2330 b C trough = C 24 for OBV, PTV and RTV; C 12 for DSV and RBV Plasma C trough from Phase 3 studies were determined using binned time intervals of >22-26 hours for OBV, PTV and RTV and >10-14 hours for DSV and RBV a. n=1253 b. n = 897 1 Pockros K et al. Gastroenterology2016 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 15

Conclusions In the presence of the 3D regimen in HCV/HIV co-infected adults DRV AUC and C max were comparable to DRV/ritonavir 800/100 mg QD or 600/100 mg BID alone DRV C 24 after DRV 800 mg QD decreased 36% and DRV C 12 after 600 mg BID decreased 27% when administered with the 3D regimen 87% of DRV C trough values in subjects taking DRV QD and 95% in DRV BID were above 550 ng/ml (EC 50 for resistant virus). None of the concentrations below the EC 50 were associated with a plasma HIV RNA >40 copies/ml Exposures of DAAs and RBV in combination with DRV are similar compared to exposures reported in healthy volunteers and HCV mono-infected adults 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 16

Acknowledgements Volunteers Investigators Study staff AbbVie personnel involved in study conduct, sample analyses, data analyses 17TH INTERNATIONAL 16TH INTERNATIONAL WORKSHOP WORKSHOP ON CLINICAL ON CLINICAL PHARMACOLOGY OF HIV && HEPATITIS THERAPY THERAPY 17